Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

August 29, 2025

Study Completion Date

August 29, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Flotufolastat (18F)

Positron emission tomography (PET)

DRUG

piflufolastat (18F)

Positron emission tomography (PET)

Trial Locations (9)

10461

Montefiore Medical Center, The Bronx

32224

Mayo Clinic, Jacksonville

44195

Cleveland Clinic, Cleveland

60026

Endeavor Health- Glenbrook Hospital, Glenview

68130

XCancer Omaha/Urology Cancer Center, Omaha

78229

Urology San Antonio, San Antonio

85054

Mayo Clinic, Phoenix

90048

Tower Urology, Los Angeles

91010

City of Hope Medical Center, Duarte

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Aixial Group

INDUSTRY

lead

Blue Earth Diagnostics

INDUSTRY